Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study

British Journal of Cancer

Volumn 99, Issue 1, 2008, Pages 133-135

  Haug, U ^a   Hundt, S ^a   Brenner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colorectal adenomas; Faecal tumour M2 pyruvate kinase; Screening; Stool testing

Indexed keywords

PYRUVATE KINASE; TUMOR M2 PYRUVATE KINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; EARLY DIAGNOSIS; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY;

EID: 46349099567     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604427     Document Type: Article

References (10)

1. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL (2006) Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 355: 2533-2541
2. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU (2004) Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91: 980-984
3. Haug U, Wente MN, Seiler CM, Rothenbacher D, Buchler MW, Brenner H (2006) Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. Clin Chem 52: 782-784
4. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H (2007) Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 96: 1329-1334
5. Koss K, Maxton D, Jankowski JA (2008) Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 10: 244-248
6. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E (2002) Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 87(Suppl 1): 23-S29
7. Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ (2007) Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 19: 878-882
8. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein JM (2006) Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 119: 2651-2656
9. Tonus C, Neupert G, Sellinger M (2006) Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 12: 7007-7011
10. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Möslein G (2005) Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 130: 872-877